Chr. Hansen has reported revenue of €756 million (US$959 million) in 2013/2014, compared to €738 million in 2012/13.
This represents an organic growth of 8%.
For 2014/15, the company expect organic revenue growth of 7-9% and an EBIT margin before special items is expected to be above 26.5%.
Research and development expenditures incurred 7-8% of revenue.
“The cultures and enzymes division and the health and nutrition division delivered solid organic growth of 8% and 15% respectively, while the natural colors division delivered organic growth of 2% excluding carmine price effect,” says Chr. Hansen CEO Cees de Jong.
“The implementation of our Nature’s No. 1 strategy saw good progress during 2013/14 and we will take this further in 2014/15, with increasing investment in our new strategic initiatives for biological plant protection and the establishment of a dedicated sales and application organization in the natural colors division.”
